Twelve-month changes in lipid-derived cardiovascular risk indices among patients with psoriasis receiving biologic therapy: a multicenter real-world retrospective cohort study

EXPERT OPINION ON BIOLOGICAL THERAPY · Published 2026-07-29 · DOI 10.1080/14712598.2026.2712432

Authors (5)

Bahadır Aslancan, Nur Ecer, Ayşegül Tel Kankılıç, Ömer Karakoyun, Kadir Kaya

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Aslancan, B., Ecer, N., Kankılıç, A., et al. (2026). Twelve-month changes in lipid-derived cardiovascular risk indices among patients with psoriasis receiving biologic therapy: a multicenter real-world retrospective cohort study. EXPERT OPINION ON BIOLOGICAL THERAPY. https://doi.org/10.1080/14712598.2026.2712432

Related articles

• Aflibercept-ayyh (aflibercept 2 mg biosimilar) for treatment-naïve retinal vascular diseases: early real-world experience – the APEX study · EXPERT OPINION ON BIOLOGICAL THERAPY · 2026 · Same journal
• Efficacy of intravenous infliximab in axial spondyloarthritis: impact on disease activity, quality of life, and productivity in subgroups with psoriasis and inflammatory bowel disease · EXPERT OPINION ON BIOLOGICAL THERAPY · 2026 · Same journal
• Anakinra treatment practices in colchicine-resistant familial Mediterranean fever: a survey of pediatric rheumatologists conducted through the PReS AID-WP and the Turkish pediatric rheumatology associations · EXPERT OPINION ON BIOLOGICAL THERAPY · 2026 · Same journal
• Immunotherapy for patients with melanoma in East Asia: current evidence, future directions, and clinical implications · EXPERT OPINION ON BIOLOGICAL THERAPY · 2026 · Same journal
• Targeting the neuroimmune axis in prurigo nodularis: a critical appraisal of the nemolizumab trials · EXPERT OPINION ON BIOLOGICAL THERAPY · 2026 · Same journal
• The role of monoclonal antibodies in the treatment of lupus nephritis · EXPERT OPINION ON BIOLOGICAL THERAPY · 2026 · Same journal
• Identification of plaque psoriasis subgroups based on peripheral blood immune cells subtypes and their relationship with biologic therapy efficacy: a single-center longitudinal cohort study in China · EXPERT OPINION ON BIOLOGICAL THERAPY · 2026 · Same journal
• Biosimilars as antivirals: scientific and regulatory readiness for rapid, cost-effective deployment in infectious threats · EXPERT OPINION ON BIOLOGICAL THERAPY · 2026 · Same journal
• Potential of new BCMA-targeting therapies in overcoming resistance in multiple myeloma · EXPERT OPINION ON BIOLOGICAL THERAPY · 2026 · Same journal
• Successful dose reduction of dupilumab in pediatric patients with atopic dermatitis in daily practice: results from the BioDay registry · EXPERT OPINION ON BIOLOGICAL THERAPY · 2026 · Same journal